nach oben

Journal of Occupational Rehabilitation

Erschienen in:

01.12.2015

Validation of the Chinese Version of the Cognitive Symptom Checklist-Work-21 in Breast Cancer Survivors

verfasst von: Andy S. K. Cheng, Yingchun Zeng, Michael Feuerstein

Erschienen in: Journal of Occupational Rehabilitation | Ausgabe 4/2015

Einloggen, um Zugang zu erhalten

Abstract

Purpose The purpose of this study was to translate the Cognitive Symptom Checklist-Work-21 (CSC-W21), into Chinese, and culturally adapt and validate the Chinese version, a measure of work-related cognitive limitations in occupationally active breast cancer survivors (BCS). Methods The translation of the English version of the CSC-W21 followed a systematic procedure. Exploratory factor analysis was used to identify factor structures. The internal consistency of the factors was assessed by calculating the Cronbach’s alpha reliability coefficients. Item- and scale-level content validity was determined. The intra-class correlation coefficient (ICC) was used to analyze test–retest reliability. A total of two hundred and twenty BCS participated in the psychometric testing of the CSC-W21-C. The construct validity of the total score of the CSC-W21-C was determined through convergent validity and an analysis of its relationship with the four subscales of the Work Limitations Questionnaire (WLQ), a measure of four types of job task difficulties. Results The CSC-W21-C demonstrated item- and scale-level content validity (>.80). The factor structure of the CSC-W21-C was similar to the original English version. The internal consistency of the subscales of the CSC-W21-C ranged from .84 to .95. The ICC was between .80 and .96 indicating good test–retest reliability. The CSC-W21-C was significantly correlated with the WLQ, particularly the mental-interpersonal subscale, where it accounted for 27.3 % of the total variance. Conclusions The findings indicate that the CSC-W21-C has sound measurement properties that strongly suggest it can be used in future assessment and intervention research to identify cognitive limitations related to specific work tasks in BCS.

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefPubMed

Fantoni SQ, Peugniez C, Duhamel A, Skrzypczak J, Frimat P, Leroyer A. Factors related to return to work by women with breast cancer in Northern France. J Occup Rehabil. 2010;20:49–58.CrossRefPubMed

Linos E, Spanos D, Rosner BA, Linos K, Hesketh T, Qu JD, et al. Effects of reproductive and demographic changes on breast cancer incidence in China: a modeling analysis. J Natl Cancer Inst. 2008;100(19):1352–60.PubMedCentralCrossRefPubMed

China National Cancer Institute. 2012 Annual Oncology Report. Ministry of Health, Bureau of Disease Prevention, Beijing.

Roelen CA, Koopmans PC, van Rhenen W, Groothoff JW, van der Klink JJ, Bültmann U. Trends in return to work of breast cancer survivors. Breast Cancer Res Treat. 2011;128(1):237–42.CrossRefPubMed

US National Cancer Institute. The SEER cancer statistics review, 1975–2010. Bethesda, MD. http://seer.cancer.gov/csr/1975_2010/results_merged/topic_survival_by_yeardx.pdf. Accessed 15 April 2014.

Liu S, Zhao J, Liu J, Sun ZP, Hua YQ, Lu DM, et al. Effects of mastectomy on the 5-year recurrence rate in breast cancer patients. J Chin Integr Med. 2008;6(10):1000–4 [in Chinese].CrossRef

Bouknight RR, Bradley CJ, Luo Z. Correlates of return to work for breast cancer survivors. J Clin Oncol. 2006;24:345–53.CrossRefPubMed

Quesnel C, Savard J, Ivers H. Cognitive impairments associated with breast cancer treatments: results from a longitudinal study. Breast Cancer Res Treat. 2009;116(1):113–23.CrossRefPubMed

10.

Ahles TA, Saykin AJ, McDonald BC, Furstenberg CT, Cole BF, Hanscom BS, et al. Cognitive function in breast cancer patients prior to adjuvant treatment. Breast Cancer Res Treat. 2008;110(1):143–52.PubMedCentralCrossRefPubMed

11.

Stewart A, Bielajew C, Collins B, Parkinson M, Tomiak E. A meta-analysis of the neuropsychological effects of adjuvant chemotherapy treatment in women treated for breast cancer. Clin Neuropsychol. 2006;20:76–89.CrossRefPubMed

12.

Falleti MG, Sanfilippo A, Maruff P, Weih L, Phillips KA. The nature and severity of cognitive impairment associated with adjuvant chemotherapy in women with breast cancer: a meta-analysis of the current literature. Brain Cogn. 2005;59:60–70.CrossRefPubMed

13.

Von Ah D, Harvison KW, Monahan PO, Moser LR, Zhao Q, Carpenter JS, et al. Cognitive function in breast cancer survivors compared to healthy age- and education-matched women. Clin Neuropsychol. 2009;23(4):661–74.CrossRef

14.

Fan HG, Houédé-Tchen N, Yi QL, Chemerynsky I, Downie FP, Sabate K, Tannock IF. Fatigue, menopausal symptoms, and cognitive function in women after adjuvant chemotherapy for breast cancer: 1- and 2- year follow-up of a prospective controlled study. J Clin Oncol. 2005;23(31):8025–32.CrossRefPubMed

15.

Bender CM, Pacella ML, Sereika SM, Brufsky AM, Vogel VG, Rastogi P, et al. What do perceived cognitive problems reflect? J Support Oncol. 2008;6(5):238–42.PubMedCentralPubMed

16.

Palmer J, Trotter T, Joy A, Carlson L. Cognitive effects of tamoxifen in pre-menopausal women with breast cancer compared to healthy controls. J Cancer Surviv. 2008;2(4):275–82.CrossRefPubMed

17.

Eberling J, Wu C, Tong-Turnbeaugh R, Jagust W. Estrogen- and tamoxifen-associated effects on brain structure and function. Neuroimage. 2004;21(1):364–71.CrossRefPubMed

18.

Hind D, Ward S, De Nigris E, Simpson E, Carroll C, Wyld LD. Hormonal therapies for early breast cancer: systematic review and economic evaluation. Health Technol Assess. 2007;11(26):iii–iv, ix–xi, 1–134.

19.

Bender CM, Sereika SM, Brufsky AM, Ryan CM, Vogel VG, Rastogi P, et al. Memory impairments with adjuvant anastrozole versus tamoxifen in women with early-stage breast cancer. Menopause. 2007;14(6):995–8.PubMedCentralCrossRefPubMed

20.

Wefel JS, Lenzi R, Theriault RL, Davis RN, Meyers CA. The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial. Cancer. 2004;100:2292–9.CrossRefPubMed

21.

Wagner LI, Cella D. Fatigue and cancer: causes, prevalence and treatment approaches. Br J Cancer. 2004;91:822–8.PubMedCentralPubMed

22.

Deimling GT, Bowman KF, Sterns S, Wagner LJ, Kahana B. Cancer-related health worries and psychological distress among older adult, long-term cancer survivors. Psychooncology. 2006;15:306–20.CrossRefPubMed

23.

Gandubert C, Carrière I, Escot C, Soulier M, Hermès A, Boulet P, et al. Onset and relapse of psychiatric disorders following early breast cancer: a case–control study. Psychooncology. 2009;18:1029–37.CrossRefPubMed

24.

Jenkins V, Shilling V, Fallowfield L, Howell A, Hutton S. Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition? A pilot study. Psychooncology. 2004;13(1):61–6.CrossRefPubMed

25.

Hansen JA, Feuerstein M, Calvio LC, Olsen CH. Breast cancer survivors at work. J Occup Environ Med. 2008;50(7):777–84.CrossRefPubMed

26.

de Boer AGEM. Work ability and return-to-work in cancer patients. Br J Cancer. 2008;98(8):1342–7.PubMedCentralCrossRefPubMed

27.

Mehnert A. Employment and work related issues in cancer survivors. Crit Rev Oncol Hematol. 2011;77:109–30.CrossRefPubMed

28.

Amir Z, Neary D, Luker K. Cancer survivors’ views of work 3 years post diagnosis: a UK perspective. Eur J Oncol Nurs. 2008;12:190–7.CrossRefPubMed

29.

Balak F, Roelen CA, Koopmans PC, ten Berge EE, Groothoff JW. Return to work after early-stage breast cancer: a cohort study into the effects of treatment and cancer-related symptoms. J Occup Rehabil. 2008;18:267–72.CrossRefPubMed

30.

Pryce J. Cancer survivorship and work: symptoms, supervisor response, co-worker disclosure and work adjustment. J Occup Rehabil. 2007;17(1):83–92.CrossRefPubMed

31.

Spelten E, Verbeek J, Uitterhoeve AL, Ansink AC, van der Lelie J, de Reijke TM, et al. Cancer, fatigue and the return of patients to work—a prospective cohort study. Eur J Cancer. 2003;39:1562–7.CrossRefPubMed

32.

Wagner L, Sweet J, Butt Z, Lai J, Cella D. Measuring patient self reported cognitive function: development of the Functional Assessment of Cancer Therapy-Cognitive Function Instrument. J Support Oncol. 2009;7:W32–9.

33.

Breckenridge LM, Bruns GL, Todd BL, Feuerstein M. Cognitive limitations associated with tamoxifen and aromatase inhibitors in employed breast cancer survivors. Psychooncology. 2012;21(1):43–53.CrossRefPubMed

34.

Ottati A, Feuerstein M. Brief self-report measure of work-related cognitive limitations in breast cancer survivors. J Cancer Surviv. 2013;7:262–73.CrossRefPubMed

35.

Guillemin F, Bombardier C, Beaton D. Cross-cultural adaptation of health-related quality of life measures: literature review and proposed guidelines. J Clin Epidemiol. 1993;46(12):1417–32.CrossRefPubMed

36.

Beaton DE, Bombardier C, Guillemin F, Ferraz MB. Guidelines for the process of cross-cultural adaptation of self-report measures. Spine. 2000;25(24):3186–91.CrossRefPubMed

37.

Polit DF, Beck CT, Owen SV. Is the CVI an acceptable indicator of content validity? Appraisal and recommendations. Res Nurs Health. 2007;30:459–67.CrossRefPubMed

38.

Portney LG, Watkins MP. Foundations of Clinical Research: Application to Practice. 3rd ed. London: Prentice-Hall; 2009.

39.

Calvio L, Peugeot M, Bruns GL, Todd BL, Feuerstein M. Measures of cognitive function and work in occupationally active breast cancer survivors. J Occup Environ Med. 2010;52(2):219–27.CrossRefPubMed

40.

Feuerstein M, Hansen JA, Calvio LC, Johnson L, Ronquillo JG. Work productivity in brain tumor survivors. J Occup Environ Med. 2007;49:803–11.CrossRefPubMed

41.

Centers for Disease Control and Prevention. Behavioral Risk Factor Surveillance Systems Survey Questionnaire: US Department of Health and Human Services. Atlanta, GA: Centers for Disease Control and Prevention; 1999.

42.

Lerner D, Amick BC III, Rogers WH, Malspeis S, Bungay K, Cynn D. The Work Limitations Questionnaire. Med Care. 2001;39:72–85.CrossRefPubMed

43.

Tamminga SJ, Verbeek J, Frings-Dresen M, Boer A. Measurement properties of the Work Limitations Questionnaire were sufficient among cancer survivors. Qual Life Res. 2014;23:515–25.CrossRefPubMed

44.

Bjelland I, Dahl A, Haug T, Neckelmann D. The validity of the Hospital Anxiety and Depression Scale: an updated literature review. J Psychosom Res. 2002;52:69–77. doi:10.1016/S0022-3999(01)00296-3.CrossRefPubMed

45.

Katz MR, Kopek N, Waldron J, Devins GM, Tomlinson G. Screening for depression in head and neck cancer. Psychooncology. 2004;13:269–80.CrossRefPubMed

46.

Alexander S, Palmer C, Stone PC. Evaluation of screening instruments for depression and anxiety in breast cancer survivors. Breast Cancer Res Treat. 2010;122(2):573–8.CrossRefPubMed

47.

Leung CM, Ho S, Kan CS. Evaluation of the Chinese version of the hospital anxiety and depression scale: a cross-cultural perspective. Int J Psychosom. 1993;40:29–34.PubMed

48.

Huang H, Zhang J, Deng XM, Xu L. Application status of psychological rating scales for patients with cancer. Nurs J Chin PLA. 2006;23(5):59–62 (in Chinese).

49.

Zhang W, Wang W, Hong J, Chen Y. Research on critical value of Hospital Anxiety and Depression Scale in screening anxiety and depression of hospitalized cancer patients. Chin J Nurs. 2012;19:1–4 (in Chinese).

50.

Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, et al. Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol. 1993;11(3):570–9.PubMed

51.

Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365–76.CrossRefPubMed

52.

53.

Zhao H, Kanda K. Testing psychometric properties of the standard Chinese version of the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire 30 (EORTC QLQC30). J Epidemiol. 2004;14(6):193–203.CrossRefPubMed

54.

Shilling V, Jenkins V. Self-reported cognitive problems in women receiving adjuvant therapy for breast cancer. Eur J Oncol Nurs. 2007;11(1):6–15.CrossRefPubMed

55.

Biglia N, Bounous VE, Malabaila A, Palmisano D, Torta DM, D’Alonzo M, et al. Objective and self-reported cognitive dysfunction in breast cancer women treated with chemotherapy: a prospective study. Eur J Cancer Care (Engl). 2012;21(4):485–92.CrossRef

56.

Munir F, Kalawsky K, Lawrence C, Yarker J, Haslam C, Ahmed S. Cognitive intervention for breast cancer patients undergoing adjuvant chemotherapy: a needs analysis. Cancer Nurs. 2011;34(5):385–92.CrossRefPubMed

57.

Todd BL, Feuerstein EL, Feuerstein M. When breast cancer survivors report cognitive problems at work. Int J Psychiatry Med. 2011;42(3):279–94.CrossRefPubMed

58.

Chan RCK, Shum D, Toulopoulou T, Chen EYH. Assessment of executive functions: review of instruments and identification of critical issues. Arch Clin Neuropsychol. 2008;23(2):201–16.CrossRefPubMed

59.

Feuerstein M, Hansen JA, Calvio LC, Johnson L, Ronquillo JG. Work productivity in brain tumor survivors. J Occup Environ Med. 2007;49(7):803–11.CrossRefPubMed

60.

Lezak MD. Neuropsychological assessment. 3rd ed. New York: Oxford University Press; 1995.

61.

Feuerstein M, Todd BL, Moskowitz MC, Bruns GL, Stoler MR, Nassif T, et al. Work in cancer survivors: a model for practice and research. J Cancer Surviv. 2010;4(4):415–37.CrossRefPubMed

62.

Maunsell E, Drolet M, Brisson J, Brisson C, Mâsse B, Deschênes L. Work situation after breast cancer: results from a population-based study. J Natl Cancer Inst. 2004;96:1813–21.CrossRefPubMed

63.

Kennedy F, Haslam C, Munir F, Pryce J. Returning to work following cancer: a qualitative exploratory study into the experience of returning to work following cancer. Eur J Cancer Care. 2007;16:17–25.CrossRef

64.

Netherlands Society of Occupational Medicine. Cancer and Work (in Dutch). http://nvab.artsennet.nl/Artikel-3/Blauw druk-Kanker-en-Werk.htm. Accessed 15 April 2014.

65.

Gonzalez-Calvo J, Gonzalez VM, Lorig K. Cultural diversity issues in the development of valid and reliable measures of health status. Arthritis Care Res. 1997;10:448–56.CrossRefPubMed

Titel: Validation of the Chinese Version of the Cognitive Symptom Checklist-Work-21 in Breast Cancer Survivors
verfasst von: Andy S. K. Cheng
Yingchun Zeng
Michael Feuerstein
Publikationsdatum: 01.12.2015
Verlag: Springer US
Erschienen in: Journal of Occupational Rehabilitation / Ausgabe 4/2015
Print ISSN: 1053-0487
Elektronische ISSN: 1573-3688
DOI: https://doi.org/10.1007/s10926-015-9576-3

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2015

What Challenges Manual Workers’ Ability to Cope with Back Pain at Work, and What Influences Their Decision to Call in Sick?

The Predictive Validity of the Return-to-Work Self-Efficacy Scale for Return-to-Work Outcomes in Claimants with Musculoskeletal Disorders

Workstyle and Musculoskeletal Discomfort (MSD): Exploring the Influence of Work Culture in Malaysia

Manager Experiences with the Return to Work Process in a Large, Publically Funded, Hospital Setting: Walking a Fine Line

Burden of Sickness Absence Due to Chronic Disease in the Dutch Workforce from 2007 to 2011

My Well-Being in My Own Hands: Experiences of Beneficial Recovery During Burnout Rehabilitation